Want to see IN:ALEMBICLTD full AI Analyst Report?
Top Page
Alembic Limited
(ALEMBICLTD)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹123.00
▲(18.96% Upside)
Action:Reiterated
Date:08/23/26
The score is driven primarily by strong financial stability (very low leverage and solid multi-year revenue growth) and attractive valuation (low P/E with a reasonable dividend yield). Technicals are supportive with price above key moving averages and positive MACD, but the main risk tempering the score is earnings quality/cash-flow consistency, given prior volatility and the unusual net income versus revenue relationship despite recent cash flow improvement.
Positive Factors
Conservative Balance Sheet
Minimal leverage reduces solvency and refinancing risk, preserving financial flexibility during operating volatility. A conservatively financed balance sheet can support continued investment in pharmaceutical products and manufacturing while limiting the burden of interest costs on future cash generation.
Negative Factors
Operating Profitability Decline
The decline in EBITDA and EBIT shows that recent revenue growth has not translated consistently into stronger operating profit. Persistent pressure on operating profitability could constrain reinvestment, reduce earnings durability, and make future results more dependent on non-operating items.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Minimal leverage reduces solvency and refinancing risk, preserving financial flexibility during operating volatility. A conservatively financed balance sheet can support continued investment in pharmaceutical products and manufacturing while limiting the burden of interest costs on future cash generation.
Read all positive factors
Alembic Limited (ALEMBICLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹27.77B
Dividend Yield2.19%
Average Volume (3M)135.56K
Price to Earnings (P/E)8.8
Beta (1Y)1.29
Revenue Growth8.21%
EPS Growth1.31%
CountryIN
Employees285
SectorGeneral
Sector StrengthN/A
IndustryReal Estate - Development
Share Statistics
EPS (TTM)12.48
Shares Outstanding256,781,830
10 Day Avg. Volume326,490
30 Day Avg. Volume135,562
Financial Highlights & Ratios
PEG Ratio2.67
Price to Book (P/B)0.74
Price to Sales (P/S)7.59
P/FCF Ratio17.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alembic Limited Business Overview & Revenue Model
Company Description
Alembic Limited primarily manufactures and globally distributes active pharmaceutical ingredients (APIs) developed through both fermentation and chemical synthesis. The company operates across two distinct divisions: API and Real Estate. In its re...
How the Company Makes Money
Alembic Limited generates revenue primarily from the sale of pharmaceutical products. Key revenue streams typically include: (1) Domestic branded formulations: earnings from marketing and selling branded medicines in India through its sales and di...
Alembic Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.39B | 2.40B | 2.22B | 1.57B | 1.18B | 713.69M |
| Gross Profit | 1.23B | 1.14B | 1.53B | 872.46M | 702.07M | 404.50M |
| EBITDA | 1.53B | 904.60M | 1.69B | 1.12B | 939.86M | 1.03B |
| Net Income | 3.21B | 3.17B | 3.11B | 2.69B | 1.91B | 2.22B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 25.90B | 25.03B | 23.29B | 22.05B | 26.32B |
| Cash, Cash Equivalents and Short-Term Investments | 980.38M | 999.00M | 582.80M | 129.05M | 464.09M | 270.77M |
| Total Debt | 0.00 | 106.40M | 144.50M | 91.49M | 0.00 | 0.00 |
| Total Liabilities | -24.45B | 1.44B | 1.64B | 1.43B | 1.27B | 1.35B |
| Stockholders Equity | 24.45B | 24.45B | 23.39B | 21.86B | 20.78B | 24.97B |
Cash Flow | ||||||
| Free Cash Flow | 257.50M | 1.06B | 356.00M | -336.03M | 130.35M | -535.60M |
| Operating Cash Flow | 489.60M | 1.82B | 863.70M | 226.87M | 388.52M | -177.47M |
| Investing Cash Flow | 135.10M | -1.18B | -265.80M | 258.36M | 72.96M | 188.48M |
| Financing Cash Flow | -639.70M | -652.20M | -583.40M | -481.94M | -463.88M | -58.16M |
Alembic Limited Technical Analysis
Positive
103.40
Price Trends
91.07
Positive
89.38
Positive
90.08
Positive
Market Momentum
5.46
Negative
71.75
Negative
65.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Positive. The current price of 103.4 is above the 20-day moving average (MA) of 96.60, above the 50-day MA of 91.07, and above the 200-day MA of 90.08, indicating a bullish trend. The MACD of 5.46 indicates Negative momentum. The RSI at 71.75 is Negative, neither overbought nor oversold. The STOCH value of 65.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALEMBICLTD.
Alembic Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹27.77B | 8.79 | ― | 2.19% | 8.21% | 1.31% | |
65 Neutral | ₹29.65B | 15.47 | ― | 0.36% | 5.31% | 54.09% | |
61 Neutral | ₹23.07B | 15.03 | ― | 0.77% | 43.12% | 12.31% | |
61 Neutral | ₹30.99B | 15.50 | ― | 0.22% | -1.06% | -29.61% | |
59 Neutral | ₹26.98B | 27.78 | ― | 0.84% | 28.63% | -26.47% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹23.27B | -535.17 | ― | 0.80% | 10.53% | -102.59% |
* General Sector Average
IN:ALEMBICLTD
Alembic Limited
109.52
9.17
9.14%
IN:AJMERA
Ajmera Realty & Infra India Ltd
118.00
-83.47
-41.43%
IN:ARKADE
Arkade Developers Limited
123.75
-54.95
-30.75%
IN:ARVSMART
Arvind SmartSpaces Ltd.
630.65
11.29
1.82%
IN:HUBTOWN
Hubtown Limited
185.45
-150.10
-44.73%
IN:MARATHON
Marathon Nextgen Realty Limited
446.65
-170.53
-27.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.